SP1通过针对USP5促进三阴性乳腺癌的进展
Shi-Yi Wu1, Zi-Mei Peng1, Feng-Yi Deng1
1Institute of Clinical Medicine, Jiangxi Provincial People's Hospital, The First Affiliated Hospital of Nanchang Medical College, 152 Aiguo Road, Nanchang, Jiangxi, 330006, China.
Cancer cell international
|May 15, 2025
概括
升高的USP5表达驱动三阴性乳腺癌 (TNBC) 的进展,由SP1.1调解. 化合物环素抑制USP5,为TNBC提供了潜在的新疗法.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 生物化学 生物化学
背景情况:
- 三阴性乳腺癌 (TNBC) 缺乏向治疗,预后不好.
- 了解TNBC的分子驱动因素对于确定新的治疗点至关重要.
- 目前尚不清楚USP5在TNBC病原发生中的作用.
研究的目的:
- 研究USP5在TNBC中的表达和功能.
- 在TNBC中阐明USP5的监管机制.
- 评估罗素作为TNBC治疗的潜在USP5抑制剂.
主要方法:
- 利用TCGA数据库,IHC,RT-PCR和西方抹杀来评估USP5和SP1的表达.
- 采用基于细胞的测试和异种移植模型来研究TNBC的进展.
- 通过化酶和ChIP-qPCR测定研究了USP5调节.
- 使用分子对接和生物化学测试对USP5抑制剂进行选.
主要成果:
- 在TNBC中,USP5表达上调,与较差的生存率相关.
- SP1通过与其促进体结合来对USP5进行转录上调,从而促进TNBC的进展.
- 佩里普洛辛有效抑制USP5活动,并阻碍TNBC的发展.
结论:
- SP1-USP5轴是TNBC进展的关键驱动力.
- 针对USP5的环素向是TNBC的一个有希望的治疗策略.
- 这些发现为开发新型TNBC治疗提供了基础.
相关概念视频
Abnormal Proliferation
4.4K
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.4K
Tumor Progression
6.2K
Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
6.2K
The Intrinsic Apoptotic Pathway
5.7K
Internal cellular stress, such as cellular injury or hypoxia, triggers intrinsic apoptosis. The B-cell lymphoma 2 (Bcl-2) family of proteins are the primary regulators of the intrinsic apoptotic pathway. For example, during DNA damage, checkpoint proteins, such as Ataxia Telangiectasia Mutated (ATM protein) and Checkpoints Factor-2 (Chk2) proteins, are activated. These proteins phosphorylate p53 which further activates pro-apoptotic proteins, such as Bax, Bak, PUMA, and Noxa, and inhibits...
5.7K
mTOR Signaling and Cancer Progression
3.7K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
3.7K
Interactions Between Signaling Pathways
6.2K
Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
6.2K
Targeted Cancer Therapies
7.4K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.4K


